verzenios
eli lilly nederland b.v. - abemaciclib - krūties navikai - antinavikiniai vaistai - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
letrozol actiopharma
actiofarma, uab - letrozolas - plėvele dengta tabletė - 2,5 mg - letrozole
paroxetine aurobindo
actiofarma, uab - paroksetinas - plėvele dengtos tabletės - 20 mg - paroxetine
paroxetine aurobindo
actiofarma, uab - paroksetinas - plėvele dengtos tabletės - 30 mg - paroxetine
anastrozole actiopharma
actiofarma, uab - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
letrozol sandoz
lex ano, uab - letrozolas - plėvele dengtos tabletės - 2,5 mg - letrozole
letrozol teva
lex ano, uab - letrozolas - plėvele dengtos tabletės - 2,5 mg - letrozole
letrozol alvogen
lex ano, uab - letrozolas - plėvele dengtos tabletės - 2,5 mg - letrozole
tamoxifeno farmoz
edupharma, uab - tamoksifenas - tabletės - 20 mg - tamoxifen
paroxetine aurobindo
ideal trade links, iĮ - paroksetinas - plėvele dengtos tabletės - 30 mg - paroxetine